Cellectis SA (CLLS) - Total Liabilities
Based on the latest financial reports, Cellectis SA (CLLS) has total liabilities worth $248.82 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Cellectis SA cash flow conversion to assess how effectively this company generates cash.
Cellectis SA - Total Liabilities Trend (2007–2025)
This chart illustrates how Cellectis SA's total liabilities have evolved over time, based on quarterly financial data. Check Cellectis SA liquidity resilience to evaluate the company's liquid asset resilience ratio.
Cellectis SA Competitors by Total Liabilities
The table below lists competitors of Cellectis SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Western New England Bancorp Inc
NASDAQ:WNEB
|
USA | $2.49 Billion |
|
Transcontinental Inc
TO:TCL-A
|
Canada | CA$1.37 Billion |
|
Incap Oyj
HE:ICP1V
|
Finland | €68.95 Million |
|
CompX International Inc
NYSE MKT:CIX
|
USA | $17.56 Million |
|
Liaoning Kelong Fine ChemicalInc
SHE:300405
|
China | CN¥602.86 Million |
|
Forcecon Technology Co Ltd
TWO:3483
|
Taiwan | NT$5.20 Billion |
|
Lionheart Holdings Unit
NASDAQ:CUBWU
|
USA | $10.07 Million |
|
Resolute Holdings Management, Inc.
NASDAQ:RHLD
|
USA | $251.59 Million |
Liability Composition Analysis (2007–2025)
This chart breaks down Cellectis SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Cellectis SA market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.77 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cellectis SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cellectis SA (2007–2025)
The table below shows the annual total liabilities of Cellectis SA from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $248.82 Million | -1.46% |
| 2024-12-31 | $252.51 Million | +1.18% |
| 2023-12-31 | $249.57 Million | +84.49% |
| 2022-12-31 | $135.28 Million | -7.09% |
| 2021-12-31 | $145.60 Million | -9.35% |
| 2020-12-31 | $160.62 Million | +43.42% |
| 2019-12-31 | $112.00 Million | +121.48% |
| 2018-12-31 | $50.57 Million | +7.64% |
| 2017-12-31 | $46.98 Million | -17.05% |
| 2016-12-31 | $56.63 Million | -33.11% |
| 2015-12-31 | $84.67 Million | -10.83% |
| 2014-12-31 | $94.95 Million | +153.46% |
| 2013-12-31 | $37.46 Million | +12.10% |
| 2012-12-31 | $33.42 Million | -64.77% |
| 2011-12-31 | $94.86 Million | +396.58% |
| 2010-12-31 | $19.10 Million | +5.44% |
| 2009-12-31 | $18.12 Million | +23.92% |
| 2008-12-31 | $14.62 Million | +41.54% |
| 2007-12-31 | $10.33 Million | -- |
About Cellectis SA
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of las… Read more